



- (51) **International Patent Classification:**
C07K 16/40 (2006.01) G01N 33/53 (2006.01)
C07K 16/46 (2006.01)
- (21) **International Application Number:**
PCT/US2014/046383
- (22) **International Filing Date:**
11 July 2014 (11.07.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/845,108 11 July 2013 (11.07.2013) US
- (71) **Applicant:** WASHINGTON UNIVERSITY [US/US];
One Brookings Drive, St. Louis, Missouri 63130 (US).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** GAUT, Joseph P. [US/US];
One Brookings Drive, St. Louis, Missouri 63130 (US).
LADENSON, Jack [US/US]; One Brookings Drive, St.
Louis, Missouri 63130 (US). CRIMMINS, Dan [US/US];
One Brookings Drive, St. Louis, Missouri 63130 (US).
MODUR, Vijay [US/US]; One Brookings Drive, St.
Louis, Missouri 63130 (US).
- (74) **Agents:** RILEY-VARGAS, Rebecca et al.; Polsinelli PC,
Mark Twain Plaza III, 105 West Vandalia, Suite 400, Ed-
wardsville, IL 62025 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2015/006710 A1

(54) **Title:** MIOX ANTIBODY AND ASSAY

(57) **Abstract:** The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.

MIOX ANTIBODY AND ASSAY

GOVERNMENT SUPPORT

[0001] This invention was made with government support under P30 DK0793305 awarded by the NIH. The government has certain rights in the invention.

CROSS REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the priority of US provisional application number 61/845,108, filed July 11, 2013, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

[0003] The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.

REFERENCE TO SEQUENCE LISTING

[0004] A paper copy of the sequence listing and a computer readable form of the same sequence listing are appended below and herein incorporated by reference. The information recorded in computer readable form is identical to the written sequence listing, according to 37 C.F.R. 1.821(f).

BACKGROUND OF THE INVENTION

[0005] Acute kidney injury is common amongst hospitalized and critically ill patients and its incidence is increasing. Approximately 45% of critically ill patients and 20% of hospitalized patients develop acute kidney injury (Li PK et al. *Kidney Int.* 2013;83:372; Bellomo R, et al. *Lancet* 2012;380:756-766; Goldstein SL *Blood Purif.* 2012;33:131-137). The result is increased hospital stays, infectious complications and increased mortality at significant cost (Nash H et al. *Am J Kidney Dis.* 2002;39:930; Liangos O et al. *Clin J Am Soc Nephrol.* 2006;1:43; Xue JL et al. *J Am Soc Nephrol* 2006;17:1135; Palevsky PM *N Engl J Med.* 2009;361:1699; Himmelfarb J and Ikizler TA *Kidney Int* 2007;71:971; Schrier RW et al. *J Clin Invest.* 2004;114:5; Singbartl K et al.

Kidney Int 2012;81:819-825). Recent studies have also linked episodes of acute kidney injury with future development of chronic kidney disease (Coca SG et al. Kidney Int. 2012;81:442; Bydash JR et al. Clin J Am Soc Nephrol. 2011;6:2555). Multiple factors contribute to the development of acute kidney injury including sepsis, ischemia, drugs, intravenous contrast, and infection (Star RA Kidney Int 1998;54:1817; Thadhani R et al. N Engl J Med 1996;334:1448; Perazella MA Kidney Int. 2012;81:1172-1178; Zarjou A and Agarwal A J Am Soc Nephrol. 2011;22:999; Solomon R and Dauerman HL Circulation 2010;122:2451; Collins AJ et al. Am J Kidney Dis. 2011;57(1)(suppl 1):e1-e526).

[0006] The current standard for identifying acute kidney injury, serum creatinine, is non-specific and insensitive (Waikar SS, et al. 2009;24:3263; Bolignano D. Clin Chem Lab Med 2012;50:1495; Star RA. Kidney Int. 1998;54:1817). Serum creatinine may not increase until days after the injury has occurred or until 50% of renal function has been lost, precluding effective treatment. Additionally, conditions other than kidney injury may cause elevations in serum creatinine. Moreover, serum creatinine is unable to accurately predict glomerular filtration rate (GFR) in the non-steady state of acute kidney injury, underestimating the decline in renal function. Lastly, since serum creatinine depends on muscle mass and hepatic function, serum concentrations may differ depending on the patient's muscle content and liver function (Waikar SS, et al. Nephrol Dial Transplant 2009;24:3263; Bolignano D. Clin Chem Lab Med 2012;50:1495; Star RA. Kidney Int. 1998;54:1817).

[0007] There is a critical unmet need for a real-time, specific, and sensitive biomarker of acute kidney injury. The American Society of Nephrology, Acute Dialysis Quality Initiative, and Acute Kidney Injury Network have all prioritized the identification and validation of acute kidney injury biomarkers (Kellum JA et al. Clin J Am Soc Nephrol. 2008;3:887; Mehta RL et al. Crit Care 2007;11:R31). Early detection of acute kidney injury may allow for timely intervention and perhaps decrease its significant morbidity and mortality (Schrier RW J Am Soc Nephrol 2004;15:2756). Although multiple new drugs have been developed to treat acute kidney injury, they have not proven effective in a clinical setting (Noguchi S, et al. J Pharmacol Exp Ther

1993;267:919-26; Conger JD, et al. Kidney Int 1989;35:1126-32; Allgren RL, et al. N Engl J Med. 1997;336:828-34; Tumlin JA, et al. Am J Kidney Dis 2005;46:26-34; Hirschberg R, et al. Kidney Int. 1999;55:2423-32; Denton MD, et al. Kidney Int. 1996;50:4-14; Acker CG et al. Kidney Int. 2000;57:293-8). This has been attributed, at least partially, to the inability to detect kidney injury early. Multiple studies have investigated a variety of plasma and urine biomarkers for the diagnosis of acute kidney injury (Kashani K et al. Crit Care 2013; 17:R25; Siew ED et al. J Am Soc Nephrol. 2011;22:810; Dieterle F, et al. Nat Biotechnol. 2010;28:455; Devarajan P Nephrology (Carlton) 2010 15:419; Waikar SS and Bonventre JV Nephron Clin Pract 2008;109:c192). Although significant progress has been made, no specific, early biomarkers of acute kidney injury have translated into clinical practice.

SUMMARY OF THE INVENTION

[0008] In an aspect, the present disclosure encompasses an isolated antibody. The antibody specifically binds MIOX and recognizes an epitope within an amino acid sequence selected from the group consisting of SEQ ID NO: 21 and SEQ ID NO:22.

[0009] In another aspect, the present disclosure encompasses an isolated antibody. The antibody specifically binds MIOX and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6 with zero to two amino acid substitutions.

[0010] In still another aspect, the present disclosure encompasses an isolated antibody. The antibody specifically binds MIOX and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12 with zero to two amino acid substitutions.

[0011] In still yet another aspect, the present disclosure encompasses an isolated antibody. The antibody specifically binds MIOX and comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3 with zero to two amino acid substitutions.

[0012] In still another embodiment, the present disclosure encompasses an isolated antibody. The antibody specifically binds MIOX and comprises a light chain

CDR3 comprising the amino acid sequence of SEQ ID NO: 9 with zero to two amino acid substitutions.

[0013] In still yet another embodiment, the present disclosure encompasses a method for measuring the amount of MIOX in a biological sample. The method comprises (i) obtaining a sample of biological fluid from a subject; and (ii) measuring the amount of MIOX in the sample by immunoassay comprising at least one isolated antibody that specifically binds MIOX. The antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-12 with zero to two amino acid substitutions.

[0014] In yet still another aspect, the present disclosure encompasses a method for detecting renal injury in a subject. The method comprises (i) obtaining a biological sample from a subject; (ii) measuring the amount of MIOX in the sample by immunoassay using at least one isolated antibody that specifically binds MIOX, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-12 with zero to two amino acid substitutions; and (iii) comparing the amount of MIOX in the sample to a reference value. A greater amount of MIOX in the sample compared to the reference value indicates renal injury in the subject.

[0015] In another aspect, the present disclosure encompasses a method for detecting proximal tubular injury in a subject. The method comprises (i) obtaining a sample of biological fluid from a subject; (ii) measuring the amount of MIOX in the sample by immunoassay using at least one isolated antibody that specifically binds MIOX, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-12 with zero to two amino acid substitutions; and (iii) comparing the amount of MIOX in the sample to a reference value. A greater amount of MIOX in the sample compared to the reference value indicates proximal tubular injury in the subject.

BRIEF DESCRIPTION OF THE FIGURES

[0016] The application file contains at least one drawing executed in color. Copies of this patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0017] **FIG. 1** depicts a bar graph and image showing MIOX gene expression and MIOX protein are kidney-specific. **(A)** MIOX mRNA expression profile in mouse tissues. Bars represent MIOX microarray units (y-axis) for each tissue sample (x-axis). Samples were obtained and analyzed as described previously (Clin Chem (2006) 52, 1713-1721). **(B)** Examination of MIOX expression in human tissue homogenates using a rabbit polyclonal anti-MIOX antibody. The pre-made blot (TB37-set I, GBiosciences, Saint Louis, MO) was immunostained with R9544 and detected with goat-anti-rabbit-alkaline phosphatase.

[0018] **FIG. 2** depicts micrographs showing MIOX expression in normal human kidney. Formalin-fixed paraffin embedded human kidney tissue was stained using the rabbit polyclonal anti-MIOX antibody R9544. **(A)** This low-power view demonstrates intense staining within the renal cortex (40x). **(B)** On high power examination, the proximal tubules show strong MIOX immunoreactivity. In contrast, the adjacent distal tubules, glomeruli, and blood vessels show no significant immunoreactivity (400x).

[0019] **FIG. 3** depicts images of Western blots confirming the specificity of the anti-MIOX antibodies and images of immunoblots showing characterization of the linear epitopes for mAb 01D10 and mAb 12H06. **(A)** Western blot of 10 μ g normal human kidney homogenate (kidney) with the rabbit anti-MIOX polyclonal antibody and the mouse monoclonal antibodies 12H06 and 01D10. Recombinant GST-MIOX (rMIOX, 10 μ g) was cut with thrombin, run on the same gel, transferred to polyvinylidene difluoride, and protein stained. The protein-stained bands were subjected to Edman sequencing and confirmed to represent MIOX and GST as indicated. The remaining lanes were cut and stained with the rabbit polyclonal anti-MIOX antibody (pAb R9544), mouse monoclonal anti-MIOX antibody 12H06 (mAb 12H06), and mouse monoclonal antibody 01D10 (mAb 01D10). Nonspecific bands were identified by use of pAb R9544 (~64 and ~22 kDa) and the mAb 12H06 (~40 kDa). The only band that reacted with all

3 antibodies corresponded to recombinant MIOX (~33 kDa). **(B)** Identification of anti-MIOX antibody epitopes. Spot-peptide membrane array immunostaining for rabbit polyclonal antibody R9544, mouse monoclonal antibody 01D10 (mAb 01D10), and mouse monoclonal antibody 12H06 (mAb 12H06). Each spot comprised a 10-mer synthetic peptide: spot 1, residues 1–10; spot 2, residues 3–12; spot 3, residues 5–14 (and so on) until the entire sequence was covered. The numbers to the left of the blots correspond to the spot number at the beginning of the row. *End of the sequence. **(C)**, Representation of anti-MIOX antibody epitopes. The amino acid sequence of MIOX is shown (SEQ ID NO:29; AA 1-285). The epitope map of the rabbit polyclonal anti-MIOX antibody is italicized (SEQ ID NO:25 (AA 1-29), SEQ ID NO:26 (AA 82-97), SEQ ID NO:27 (AA 158-171), SEQ ID NO:28 (AA 272-281), mouse monoclonal antibody 12H06 is bold and underlined (SEQ ID NO:21; AA 268-279), and the mouse monoclonal antibody 01D10 is boxed (SEQ ID NO:22; AA 9-21). The mAb 01D10 antibody recognizes an epitope near the N-terminus, and the mAb 12H06 antibody recognizes an epitope near the C-terminus. The polyclonal antibody reacts with N- and C-terminal epitopes and 2 internal epitopes. **(D)** Western blot of normal kidney homogenate from human (H), mouse (M), and rat (R) (G-Biosciences, St. Louis, MO) using the 01D10 mouse monoclonal antibody. Samples were loaded at 50 µg/lane. **(E)** Western blot of human, mouse, and rat kidney homogenate using the 12H06 mouse monoclonal antibody.

[0020] **FIG. 4** depicts images of immunoblots showing confirmation of specific antibody epitopes by blocking mAb binding to endogenous MIOX. **(A)** The peptides corresponding to the epitopes for mAb 01D10 (peptide 1) and mAb 12H06 (peptide 2) were synthesized. mAb 01D10 was pre-incubated for one hour with buffer alone, 100 µg/ml peptide 1, or 100 µg/ml peptide 2. **(B)** Western inhibition of mAb 12H06 using either peptide 1 or peptide 2.

[0021] **FIG. 5** depicts results from the mouse AKI model. **(A)** Miox was measured in mouse serum from sham-operated animals, animals at baseline, and 24 hours after AKI (n = 5). Miox was below the limit of detection (LOD) [115 (55) pg/mL] in sham-operated animals and at baseline. Serum Miox was increased 24 h post-injury [2.8 (0.7)

ng/mL, mean (SE); *P < 0.03]. **(B)** Representative section of renal cortex from a sham-operated mouse shows intact renal tubules (H&E, 400x). **(C)** Representative section of renal cortex 24 h postinjury. Extensive tubular necrosis is evident (arrows) (H&E, 400x). **(D)** Blood urea nitrogen levels at baseline and 24 hours after ischemia-reperfusion injury (IRI).

[0022] **FIG. 6** shows detailed information for a single patient with acute kidney injury. **(A)** CT scan from a patient with acute kidney injury. The right kidney shows poor perfusion, consistent with ischemia. **(B)** Serum creatinine was obtained at the time of presentation to the emergency room and 33 hours later. No prior creatinine values were available for comparison. **(C)** Plasma MIOX was markedly elevated at the time of presentation. Plasma MIOX decreased, but remained detectable, 33 hours later.

[0023] **FIG. 7** shows MIOX in critically ill and hospitalized patients. **(A)** Plasma creatinine (Cr) peaked 54.3 (3.8) h (time 54) relative to the preceding Cr measurement (time 0) and was increased at time 54 in patients with AKI (**P < 0.005). **(B)** Patients with AKI showed higher plasma MIOX concentrations at time 0 and time 54 compared with patients without AKI (*P = 0.002). To convert creatinine in mg/dL to mmol/L, multiply by 0.0884.

[0024] **FIG. 8** depicts MIOX and creatinine levels in AKI patients. **(A)** Plasma creatinine is similar among all groups at time 0. **(B)** Plasma MIOX increased at time 0 in patients with oliguric and dialysis-requiring AKI. **(C)** Plasma creatinine increased at time 54 in patients with AKI. **(D)** Plasma MIOX was increased at time 54 in patients with oliguric and dialysis-requiring AKI relative to patients without AKI. *P < 0.05. To convert creatinine in mg/dL to mmol/L, multiply by 0.0884.

[0025] **FIG. 9** depicts the plasma creatinine level for four patients undergoing cardiopulmonary bypass surgery. **(A)** Patient 001 with AKI, Stage 2; **(B)** Patient 002 with no AKI; **(C)** Patient 003 with AKI, Stage 3; and **(D)** Patient 004 with AKI, Stage 1.

[0026] **FIG. 10** depicts the plasma MIOX level for four patients undergoing cardiopulmonary bypass surgery. **(A)** Patient 001 with AKI, Stage 2; **(B)** Patient 002 with no AKI; **(C)** Patient 003 with AKI, Stage 3; and **(D)** Patient 004 with AKI, Stage 1.

DETAILED DESCRIPTION

[0027] Applicants have discovered antibodies and methods of use thereof for detecting renal injury in a subject. The method comprises detecting and measuring the amount of *myo*-inositol oxygenase (MIOX) in a biological sample obtained from a subject using an anti-MIOX antibody. The present invention encompasses the discovery that MIOX is a kidney specific protein that is abundantly expressed in the proximal tubule, and it is detectable in biological fluids earlier than existing biomarkers of acute kidney injury. Thus, the invention provides evidence that detection of increased MIOX in a biological fluid following kidney injury is likely directly related to protein loss from the cells of the proximal tubule. In an aspect, an increased amount of MIOX in a biological fluid indicates proximal tubular cell damage. In another aspect, an increased amount of MIOX in a biological fluid indicates loss of MIOX from the proximal renal tubule. In still another aspect, an increased amount of MIOX in a biological fluid indicates proximal tubule injury. In still yet another aspect, an increased amount of MIOX in a biological fluid indicates renal injury associated with proximal tubule injury. In yet still another aspect, antibodies useful in detecting an increased amount of MIOX in a biological fluid include those which bind an epitope within MIOX.

I. Anti-MIOX antibodies

[0028] Anti-MIOX antibodies useful herein include all antibodies that specifically bind an epitope within MIOX. Generally speaking, the epitope is detectable following proximal tubular cell damage. The epitope may or may not be detectable in the absence of proximal tubular cell damage. For example, proximal tubular cell damage may modify the protein such that a previously undetectable epitope becomes detectable.

Alternatively, an epitope may be detectable both in the in the absence of proximal tubular cell damage and following proximal tubular cell damage, though the detectable signal is greater following proximal tubular cell damage. Anti-MIOX antibodies useful herein also include antibodies that bind to specific regions of MIOX and to other forms of MIOX. Specific regions of MIOX include, but are not limited to, the C-terminal, the N-terminal, and other central domains. Other forms of MIOX include but are not limited to

truncated, modified, soluble, insoluble, intracellular, extracellular, and dimerized or otherwise oligomerized forms, as well as MIOX complexed with other proteins or molecules.

[0029] Anti-MIOX antibodies useful herein include those which are isolated, characterized, purified, functional and have been recovered (obtained) from a process for their preparation and thus available for use herein in a useful form in an amount sufficient for an assay to detect and measure the amount of MIOX in a biological sample.

[0030] The term "antibody" includes the term "monoclonal antibody". "Monoclonal antibody" refers to an antibody that is derived from a single copy or clone, including e.g., any eukaryotic, prokaryotic, or phage clone. "Monoclonal antibody" is not limited to antibodies produced through hybridoma technology. Monoclonal antibodies can be produced using e.g., hybridoma techniques well known in the art, as well as recombinant technologies, phage display technologies, synthetic technologies or combinations of such technologies and other technologies readily known in the art. Furthermore, the monoclonal antibody may be labeled with a detectable label, immobilized on a solid phase and/or conjugated with a heterologous compound (e.g., an enzyme or toxin) according to methods known in the art.

[0031] Further by "antibody" is meant a functional monoclonal antibody, or an immunologically effective fragment thereof; such as an Fab, Fab', or F(ab')₂ fragment thereof. In some contexts herein, fragments will be mentioned specifically for emphasis; nevertheless, it will be understood that regardless of whether fragments are specified, the term "antibody" includes such fragments as well as single-chain forms. As long as the protein retains the ability specifically to bind its intended target, it is included within the term "antibody." Also included within the definition "antibody" for example are single chain forms, generally designated Fv, regions, of antibodies with this specificity.

[0032] Preferably, but not necessarily, the antibodies useful in the discovery are produced recombinantly, as manipulation of the typically murine or other non-human antibodies with the appropriate specificity is required in order to convert them to humanized form. Antibodies may or may not be glycosylated, though glycosylated

antibodies are preferred. Antibodies are properly cross-linked via disulfide bonds, as is known.

[0033] The basic antibody structural unit of an antibody useful herein comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acid sequences primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.

[0034] Light chains are classified as gamma, mu, alpha, and lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acid sequences, with the heavy chain also including a "D" region of about 10 more amino acid sequences.

[0035] The variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact antibody has two binding sites. The chains exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions (hereinafter referred to as "CDRs.") The CDRs from the two chains are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 respectively. The assignment of amino acid sequences to each domain is in accordance with known conventions (See, Kabat "Sequences of Proteins of Immunological Interest" National Institutes of Health, Bethesda, Md., 1987 and 1991; Chothia, et al, J. Mol. Bio. (1987) 196:901-917; Chothia, et al., Nature (1989) 342:878-883).

[0036] In an aspect, monoclonal anti-MIOX antibodies are generated with appropriate specificity by standard techniques of immunization of mammals, forming hybridomas from the antibody-producing cells of said mammals or otherwise immortalizing them, and culturing the hybridomas or immortalized cells to assess them

for the appropriate specificity. In the present case, such antibodies could be generated by immunizing a human, rabbit, rat or mouse, for example, with a peptide representing an epitope encompassing a region of the MIOX protein coding sequence or an appropriate subregion thereof. Materials for recombinant manipulation can be obtained by retrieving the nucleotide sequences encoding the desired antibody from the hybridoma or other cell that produces it. These nucleotide sequences can then be manipulated and isolated, characterized, purified and, recovered to provide them in humanized form, for use herein if desired.

[0037] As used herein "humanized antibody" includes an anti-MIOX antibody that is composed partially or fully of amino acid sequence sequences derived from a human antibody germline by altering the sequence of an antibody having non-human complementarity determining regions ("CDR"). The simplest such alteration may consist simply of substituting the constant region of a human antibody for the murine constant region, thus resulting in a human/murine chimera which may have sufficiently low immunogenicity to be acceptable for pharmaceutical use. Preferably, however, the variable region of the antibody and even the CDR is also humanized by techniques that are by now well known in the art. The framework regions of the variable regions are substituted by the corresponding human framework regions leaving the non-human CDR substantially intact, or even replacing the CDR with sequences derived from a human genome. CDRs may also be randomly mutated such that binding activity and affinity for MIOX is maintained or enhanced in the context of fully human germline framework regions or framework regions that are substantially human. Substantially human frameworks have at least 90%, 95%, or 99% sequence identity with a known human framework sequence. Fully useful human antibodies are produced in genetically modified mice whose immune systems have been altered to correspond to human immune systems. As mentioned above, it is sufficient for use in the methods of this discovery, to employ an immunologically specific fragment of the antibody, including fragments representing single chain forms.

[0038] Further, as used herein the term "humanized antibody" refers to an anti-MIOX antibody comprising a human framework, at least one CDR from a nonhuman

antibody, and in which any constant region present is substantially identical to a human immunoglobulin constant region, i.e., at least about 85-90%, preferably at least 95% identical. Hence, all parts of a humanized antibody, except possibly the CDRs, are substantially identical to corresponding pairs of one or more native human immunoglobulin sequences.

[0039] If desired, the design of humanized immunoglobulins may be carried out as follows. When an amino acid sequence falls under the following category, the framework amino acid sequence of a human immunoglobulin to be used (acceptor immunoglobulin) is replaced by a framework amino acid sequence from a CDR-providing nonhuman immunoglobulin (donor immunoglobulin): (a) the amino acid sequence in the human framework region of the acceptor immunoglobulin is unusual for human immunoglobulin at that position, whereas the corresponding amino acid sequence in the donor immunoglobulin is typical for human immunoglobulin at that position; (b) the position of the amino acid sequence is immediately adjacent to one of the CDRs; or (c) any side chain atom of a framework amino acid sequence is within about 5-6 angstroms (center-to-center) of any atom of a CDR amino acid sequence in a three dimensional immunoglobulin model (Queen, et al., *op. cit.*, and Co, et al, *Proc. Natl. Acad. Sci. USA* (1991) 88:2869). When each of the amino acid sequences in the human framework region of the acceptor immunoglobulin and a corresponding amino acid sequence in the donor immunoglobulin is unusual for human immunoglobulin at that position, such an amino acid sequence is replaced by an amino acid sequence typical for human immunoglobulin at that position.

[0040] In all instances, an antibody of the invention specifically binds MIOX. In exemplary embodiments, an antibody of the invention specifically binds human MIOX. The phrase "specifically binds" herein means antibodies bind to the protein with an affinity constant or Affinity of interaction (K_D) in the range of at least 0.1 mM to 1 pM, or in the range of at least 0.1 pM to 10 nM, with a preferred range being 0.1 pM to 1 nM. The sequence of MIOX from a variety of species is known in the art, and methods of determining whether an antibody binds to MIOX are known in the art. For instance, see the Examples.

[0041] The antibodies of the present invention may also be used as fusion proteins known as single chain variable fragments (scFv). These scFvs are comprised of the heavy and light chain variable regions connected by a linker. In most instances, but not all, the linker may be a peptide. A linker peptide is preferably from about 10 to 25 amino acids in length. Preferably, a linker peptide is rich in glycine, as well as serine or threonine. ScFvs can be used to facilitate phage display or can be used for flow cytometry, immunohistochemistry, or as targeting domains. Methods of making and using scFvs are known in the art.

[0042] In a preferred embodiment, the scFvs of the present invention are conjugated to a human constant domain. In some embodiments, the heavy constant domain is derived from an IgG domain, such as IgG1, IgG2, IgG3, or IgG4. In other embodiments, the heavy chain constant domain may be derived from IgA, IgM, or IgE.

[0043] An isolated antibody of the present invention that binds to MIOX preferably recognizes one of several epitopes. In one embodiment, the isolated antibody of the present invention that binds to MIOX recognizes an epitope within the amino acid sequences of SEQ ID NO: 21 (RPYYQGLIDKYC). Preferably, the isolated antibody recognizes an epitope within at least three contiguous amino acids of SEQ ID NO: 21, including within at least 4 contiguous amino acids of SEQ ID NO: 21, within at least 5 contiguous amino acids of SEQ ID NO: 21, within at least 6 contiguous amino acids of SEQ ID NO: 21, within at least 7 contiguous amino acids of SEQ ID NO: 21, within at least 8 contiguous amino acids of SEQ ID NO: 21, within at least 9 contiguous amino acids of SEQ ID NO: 21, within at least 10 contiguous amino acids of SEQ ID NO: 21, within at least 11 contiguous amino acids of SEQ ID NO: 21, and within at least 12 contiguous amino acids of SEQ ID NO: 21. In an exemplary embodiment, an isolated antibody of the present invention that recognizes an epitope within SEQ ID NO: 21 is the antibody 12H06.

[0044] In another embodiment, the isolated antibody of the present invention that binds to MIOX recognizes an epitope within the amino acid sequence of SEQ ID NO: 22 (PSLVYRPDVDPEV). Preferably, the isolated antibody recognizes an epitope within at least three contiguous amino acids of SEQ ID NO: 22, including within at least 4

contiguous amino acids of SEQ ID NO: 22, within at least 5 contiguous amino acids of SEQ ID NO: 22, within at least 6 contiguous amino acids of SEQ ID NO: 22, within at least 7 contiguous amino acids of SEQ ID NO: 22, within at least 8 contiguous amino acids of SEQ ID NO: 22, within at least 9 contiguous amino acids of SEQ ID NO: 22, within at least 10 contiguous amino acids of SEQ ID NO: 22, within at least 11 contiguous amino acids of SEQ ID NO: 22, and within at least 12 contiguous amino acids of SEQ ID NO: 22, and within at least 13 contiguous amino acids of SEQ ID NO: 22. In an exemplary embodiment, an isolated antibody of the present invention that recognizes an epitope within SEQ ID NO: 22 is the antibody 01D10.

[0045] The human MIOX protein shows 89.8%, 90.5%, 89.2%, 89.8%, 89.1%, 92.3%, and 88.8% homology with mouse, rat, pig, guinea pig, ground squirrel, cat, and dog MIOX, respectively. The antibody epitope sequence of the human and various animal epitopes show significant homology (**Table A**). In one embodiment, an antibody of the invention may recognize human MIOX. In another embodiment, an antibody of the invention may recognize rat MIOX. In another embodiment, an antibody of the invention may recognize mouse MIOX. In another embodiment, an antibody of the invention may recognize cat MIOX. In another embodiment, an antibody of the invention may recognize dog MIOX. In another embodiment, an antibody of the invention may recognize pig MIOX. Antibodies of the invention may also bind MIOX from other species.

Table A. MIOX epitope sequence similarity between human MIOX and other species

SEQ ID NO:	12H06 epitope	Species	01D10 epitope	SEQ ID NO:
21	RPYYQGLIDKYC	Human	PSLVYRPDVDPEV	22
21	RPYYQGLIDKYC	Mouse	PSLVYRPDVDPEM	30
21	RPYYQGLIDKYC	Rat	PSLVYRPDVDPEM	30
21	RPYYQGLIDKYC	Pig	PSLVYRPDVDPEA	31
21	RPYYQALIDKYC	Guinea Pig	PSLIYRPDMDPEM	32
21	RPYYQELIDKYC	Ground Squirrel	PSLVYRPDVGTEA	33

21	RPYYQGLIDKYC	Cat	PSLVYRPDVDPEA	31
21	RPYYQGLIDKYC	Dog	PSLVYRPDMDPEK	34

[0046] A preferred antibody is a mouse antibody derived from a hybridoma designated 01D10 or 12H06 (Gaut JP, et al. Clin Chem. 2014:60(5):747-57). As used herein, the term “derived from” means that the “derived” antibody comprises at least one CDR region from the antibody produced by 01D10 or 12H06. Stated another way, the “derived antibody” comprises at least one CDR region comprised of the amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.

[0047] In one embodiment, an antibody of the invention may be derived from the hybridoma 01D10, and may be encoded by a nucleic acid sequence comprising 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the light chain variable region of SEQ ID NO:17, or may be encoded by a nucleic acid sequence comprising 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the heavy chain variable region of SEQ ID NO:18. In another embodiment, an antibody of the invention may be derived from the hybridoma 01D10, and may be encoded by an amino acid sequence comprising 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the light chain variable region of SEQ ID NO:13, or may be encoded by a nucleic acid sequence comprising 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the heavy chain variable region of SEQ ID NO:14. In each of the above embodiments, the antibody may be humanized.

[0048] In a different embodiment, an antibody of the invention may be derived from the hybridoma 12H06, and may be encoded by a nucleic acid sequence comprising 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the light chain variable region of SEQ ID NO:19, or may be encoded by a nucleic acid sequence comprising 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the heavy chain variable region of SEQ ID NO:20. In another embodiment, an antibody of the invention may be derived from the hybridoma 12H06, and may be encoded by an amino acid sequence comprising 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the light chain variable region of SEQ ID NO:15, or may be encoded by an amino acid sequence comprising 90, 91, 92, 93, 94,

95, 96, 97, 98, or 99% identity to the heavy chain variable region of SEQ ID NO:16. In each of the above embodiments, the antibody may be humanized.

[0049] In an exemplary embodiment of an antibody of the invention that binds to MIOX, the antibody comprises the light chain amino acid sequence of SEQ ID NO:13 and the heavy chain amino acid sequence of SEQ ID NO:14 [i.e. the monoclonal antibody referred to herein as mAb 01D10]. In another exemplary embodiment of an antibody of the invention that binds to MIOX, the antibody comprises the light chain amino acid sequence of SEQ ID NO:15 and the heavy chain amino acid sequence of SEQ ID NO:16 [i.e. the monoclonal antibody referred to herein as mAb 12H06]. In another exemplary embodiment of an antibody of the invention that binds to MIOX, the antibody comprises the light chain nucleic acid sequence of SEQ ID NO:17 and the heavy chain amino acid sequence of SEQ ID NO:18 [i.e. the monoclonal antibody referred to herein as mAb 01D10]. In another exemplary embodiment of an antibody of the invention that binds to MIOX, the antibody comprises the light chain nucleic acid sequence of SEQ ID NO:19 and the heavy chain nucleic acid sequence of SEQ ID NO:20 [i.e. the monoclonal antibody referred to herein as mAb 12H06]. In each of the above embodiments, the antibody may be humanized.

[0050] In one embodiment, an antibody of the invention may comprise a light chain CDR1, such as the antibodies 1 and 49 of **Table B**. In another embodiment, an antibody of the invention may comprise a light chain CDR2, such as the antibodies 4 and 52 of **Table B**. In yet another embodiment, an antibody of the invention may comprise a light chain CDR3, such as the antibodies 6 and 54 of **Table B**. In an alternative embodiment, an antibody of the invention may comprise a combination of two or three light chain CDRs, such as the antibodies 2, 3, 5, 50, 51, and 53 of **Table B**. In each of the above embodiments, the antibody may be humanized.

[0051] Similarly, in one embodiment, an antibody of the invention may comprise a heavy chain CDR1, such as the antibodies 7 and 55 of **Table B**. In another embodiment, an antibody of the invention may comprise a heavy chain CDR2, such as the antibodies 10 and 58 of **Table B**. In yet another embodiment, an antibody of the invention may comprise a heavy chain CDR3, such as the antibodies 12 and 60 of

Table B. In an alternative embodiment, an antibody of the invention may comprise a combination of two or three heavy chain CDRs, such as the antibodies 8, 9, 11, 56, 57, and 59 of **Table B**. In each of the above embodiments, the antibody may be humanized.

[0052] Alternatively, an antibody of the invention may comprise one or more light chain CDRs and one or more heavy chain CDRs, such as the antibodies 13-48, and 61-96 of **Table B**. In each of the above embodiments, the antibody may be humanized.

Table B

Anti-body	Light Chain			Heavy Chain		
	CDR1	CDR2	CDR3	CDR1	CDR2	CDR3
1	SEQ ID NO:1					
2	SEQ ID NO:1	SEQ ID NO:2				
3	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3			
4		SEQ ID NO:2				
5		SEQ ID NO:2	SEQ ID NO:3			
6			SEQ ID NO:3			
7				SEQ ID NO:4		
8				SEQ ID NO:4	SEQ ID NO:5	
9				SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6
10					SEQ ID NO:5	
11					SEQ ID NO:5	SEQ ID NO:6
12						SEQ ID NO:6
13	SEQ ID NO:1			SEQ ID NO:4		
14	SEQ ID NO:1			SEQ ID NO:4	SEQ ID NO:5	
15	SEQ ID NO:1			SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6
16	SEQ ID NO:1				SEQ ID NO:5	
17	SEQ ID NO:1				SEQ ID NO:5	SEQ ID NO:6
18	SEQ ID NO:1					SEQ ID NO:6
19	SEQ ID NO:1	SEQ ID NO:2		SEQ ID NO:4		
20	SEQ ID NO:1	SEQ ID NO:2		SEQ ID NO:4	SEQ ID NO:5	
21	SEQ ID NO:1	SEQ ID NO:2		SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6
22	SEQ ID NO:1	SEQ ID NO:2			SEQ ID NO:5	
23	SEQ ID NO:1	SEQ ID NO:2			SEQ ID NO:5	SEQ ID NO:6
24	SEQ ID NO:1	SEQ ID NO:2				SEQ ID NO:6
25	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3	SEQ ID NO:4		

26	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	
27	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6
28	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3		SEQ ID NO:5	
29	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3		SEQ ID NO:5	SEQ ID NO:6
30	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3			SEQ ID NO:6
31		SEQ ID NO:2		SEQ ID NO:4		
32		SEQ ID NO:2		SEQ ID NO:4	SEQ ID NO:5	
33		SEQ ID NO:2		SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6
34		SEQ ID NO:2			SEQ ID NO:5	
35		SEQ ID NO:2			SEQ ID NO:5	SEQ ID NO:6
36		SEQ ID NO:2				SEQ ID NO:6
37		SEQ ID NO:2	SEQ ID NO:3	SEQ ID NO:4		
38		SEQ ID NO:2	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	
39		SEQ ID NO:2	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6
40		SEQ ID NO:2	SEQ ID NO:3		SEQ ID NO:5	
41		SEQ ID NO:2	SEQ ID NO:3		SEQ ID NO:5	SEQ ID NO:6
42		SEQ ID NO:2	SEQ ID NO:3			SEQ ID NO:6
43			SEQ ID NO:3	SEQ ID NO:4		
44			SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	
45			SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6
46			SEQ ID NO:3		SEQ ID NO:5	
47			SEQ ID NO:3		SEQ ID NO:5	SEQ ID NO:6
48			SEQ ID NO:3			SEQ ID NO:6
49	SEQ ID NO:7					
50	SEQ ID NO:7	SEQ ID NO:8				
51	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9			
52		SEQ ID NO:8				
53		SEQ ID NO:8	SEQ ID NO:9			
54			SEQ ID NO:9			
55				SEQ ID NO:10		
56				SEQ ID NO:10	SEQ ID NO:11	
57				SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12
58					SEQ ID NO:11	
59					SEQ ID NO:11	SEQ ID NO:12
60						SEQ ID NO:12
61	SEQ ID NO:7			SEQ ID NO:10		

62	SEQ ID NO:7			SEQ ID NO:10	SEQ ID NO:11	
63	SEQ ID NO:7			SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12
64	SEQ ID NO:7				SEQ ID NO:11	
65	SEQ ID NO:7				SEQ ID NO:11	SEQ ID NO:12
66	SEQ ID NO:7					SEQ ID NO:12
67	SEQ ID NO:7	SEQ ID NO:8		SEQ ID NO:10		
68	SEQ ID NO:7	SEQ ID NO:8		SEQ ID NO:10	SEQ ID NO:11	
69	SEQ ID NO:7	SEQ ID NO:8		SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12
70	SEQ ID NO:7	SEQ ID NO:8			SEQ ID NO:11	
71	SEQ ID NO:7	SEQ ID NO:8			SEQ ID NO:11	SEQ ID NO:12
72	SEQ ID NO:7	SEQ ID NO:8				SEQ ID NO:12
73	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9	SEQ ID NO:10		
74	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9	SEQ ID NO:10	SEQ ID NO:11	
75	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9	SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12
76	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9		SEQ ID NO:11	
77	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9		SEQ ID NO:11	SEQ ID NO:12
78	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9			SEQ ID NO:12
79		SEQ ID NO:8		SEQ ID NO:10		
80		SEQ ID NO:8		SEQ ID NO:10	SEQ ID NO:11	
81		SEQ ID NO:8		SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12
82		SEQ ID NO:8			SEQ ID NO:11	
83		SEQ ID NO:8			SEQ ID NO:11	SEQ ID NO:12
84		SEQ ID NO:8				SEQ ID NO:12
85		SEQ ID NO:8	SEQ ID NO:9	SEQ ID NO:10		
86		SEQ ID NO:8	SEQ ID NO:9	SEQ ID NO:10	SEQ ID NO:11	
87		SEQ ID NO:8	SEQ ID NO:9	SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12
88		SEQ ID NO:8	SEQ ID NO:9		SEQ ID NO:11	
89		SEQ ID NO:8	SEQ ID NO:9		SEQ ID NO:11	SEQ ID NO:12
90		SEQ ID NO:8	SEQ ID NO:9			SEQ ID NO:12
91			SEQ ID NO:9	SEQ ID NO:10		
92			SEQ ID NO:9	SEQ ID NO:10	SEQ ID NO:11	
93			SEQ ID NO:9	SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12
94			SEQ ID NO:9		SEQ ID NO:11	
95			SEQ ID NO:9		SEQ ID NO:11	SEQ ID NO:12
96			SEQ ID NO:9			SEQ ID NO:12

[0053] In one embodiment, an antibody of the invention may comprise a light chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 1 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 2 with zero to two amino acid substitutions, and a CDR3 of amino acid sequence SEQ ID NO:3 with zero to two amino acid substitutions, or may comprise a heavy chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 4 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 5 with zero to two amino acid substitutions, and a CDR3 of amino acid sequence SEQ ID NO: 6 with zero to two amino acid substitutions. In a preferred embodiment, an antibody of the invention may comprise a light chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 1 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 2 with zero to two amino acid substitutions, a CDR3 of amino acid sequence SEQ ID NO:3, a heavy chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 4 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 5 with zero to two amino acid substitutions, and a CDR3 of amino acid sequence SEQ ID NO: 6 with zero to two amino acid substitutions. In an exemplary embodiment, an antibody of the invention may comprise a light chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 1, a CDR2 of amino acid sequence SEQ ID NO: 2, a CDR3 of amino acid sequence SEQ ID NO:3, a heavy chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 4, a CDR2 of amino acid sequence SEQ ID NO: 5, and a CDR3 of amino acid sequence SEQ ID NO: 6. The invention also encompasses the corresponding nucleic acid sequences of SEQ ID NO:1, 2, 3, 4, 5, and 6, which can readily be determined by one of skill in the art, and may be incorporated into a vector or other large DNA molecule, such as a chromosome, in order to express an antibody of the invention. In each of the above embodiments, the antibody may be humanized.

[0054] In another embodiment, an antibody of the invention may comprise a light chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 7 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 8 with zero to two amino acid substitutions, and a CDR3 of amino acid sequence SEQ ID

NO: 9 with zero to two amino acid substitutions, or may comprise a heavy chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 10 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 11 with zero to two amino acid substitutions, and a CDR3 of amino acid sequence SEQ ID NO: 12 with zero to two amino acid substitutions. In a preferred embodiment, an antibody of the invention may comprise a light chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 7 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 8 with zero to two amino acid substitutions, a CDR3 of amino acid sequence SEQ ID NO: 9 with zero to two amino acid substitutions, and a heavy chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 10 with zero to two amino acid substitutions, a CDR2 of amino acid sequence SEQ ID NO: 11 with zero to two amino acid substitutions, and a CDR3 of amino acid sequence SEQ ID NO: 12 with zero to two amino acid substitutions. In an exemplary embodiment, an antibody of the invention may comprise a light chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 7, a CDR2 of amino acid sequence SEQ ID NO: 8, a CDR3 of amino acid sequence SEQ ID NO: 9, a heavy chain variable region comprising a CDR1 of amino acid sequence SEQ ID NO: 10, a CDR2 of amino acid sequence SEQ ID NO: 11, and a CDR3 of amino acid sequence SEQ ID NO: 12. The invention also encompasses the corresponding nucleic acid sequences of SEQ ID NO: 7, 8, 9, 10, 11, and 12, which can readily be determined by one of skill in the art, and may be incorporated into a vector or other large DNA molecule, such as a chromosome, in order to express an antibody of the invention. In each of the above embodiments, the antibody may be humanized.

II. Methods of using anti-MIOX antibodies

[0055] In an aspect, the present invention provides antibodies to detect MIOX in a biological sample obtained from a subject. In another aspect, the present invention provides antibodies to measure the amount of MIOX in a biological sample obtained from a subject. The amount of MIOX in a biological sample obtained from a subject can

be used to classify a subject as having high or low amounts of MIOX, and may be further used to identify in the subject renal injury associated with proximal tubule injury.

(a) Methods to detect and measure the amount of MIOX in a biological sample

[0056] In an aspect, the invention provides means to detect MIOX in a biological sample obtained from a subject. In another aspect, the invention provides means to measure the amount of MIOX in a biological sample obtained from a subject. The method generally comprises (i) obtaining a biological sample from a subject, and (ii) detecting and/or measuring the amount of MIOX in the sample using an antibody that specifically binds MIOX. Suitable antibodies are described above in **Section I**.

[0057] As used herein, the term “biological sample” refers to a sample obtained from a subject. Any biological sample containing MIOX is suitable. Numerous types of biological samples are known in the art. Suitable biological sample may include, but are not limited to, tissue samples or bodily fluids. In some embodiments, the biological sample is a tissue sample such as a tissue biopsy. The tissue biopsy may be a biopsy of kidney tissue. The biopsied tissue may be fixed, embedded in paraffin or plastic, and sectioned, or the biopsied tissue may be frozen and cryosectioned. Alternatively, the biopsied tissue may be processed into individual cells or an explant, or processed into a homogenate, a cell extract, a membranous fraction, or a protein extract. The sample may also be primary and/or transformed cell cultures derived from tissue from the subject. In other embodiments, the sample may be a bodily fluid. Non-limiting examples of suitable bodily fluids include blood, plasma, serum, and urine. The fluid may be used “as is”, the cellular components may be isolated from the fluid, or a protein fraction may be isolated from the fluid using standard techniques.

[0058] Suitable subjects include, but are not limited to, a human, a livestock animal, a companion animal, a lab animal, and a zoological animal. A subject may or may not be known to have renal injury. In one embodiment, the subject may be a rodent, e.g. a mouse, a rat, a guinea pig, etc. In another embodiment, the subject may be a livestock animal. Non-limiting examples of suitable livestock animals may include pigs, cows, horses, goats, sheep, llamas and alpacas. In yet another embodiment, the

subject may be a companion animal. Non-limiting examples of companion animals may include pets such as dogs, cats, rabbits, and birds. In yet another embodiment, the subject may be a zoological animal. As used herein, a “zoological animal” refers to an animal that may be found in a zoo. Such animals may include non-human primates, large cats, wolves, and bears. In preferred embodiments, the animal is a laboratory animal. Non-limiting examples of a laboratory animal may include rodents, canines, felines, and non-human primates. In certain embodiments, the animal is a rodent. In a preferred embodiment, the subject is human.

[0059] As will be appreciated by a skilled artisan, the method of collecting a biological sample can and will vary depending upon the nature of the biological sample and the type of analysis to be performed. Any of a variety of methods generally known in the art may be utilized to collect a biological sample. Generally speaking, the method preferably maintains the integrity of the sample such that MIOX can be accurately detected and the amount measured according to the invention.

[0060] Once a sample is obtained, it is processed *in vitro* to detect and measure the amount of MIOX using an anti-MIOX antibody. All suitable methods for detecting and measuring an amount of protein using an antibody known to one of skill in the art are contemplated within the scope of the invention. Methods for detecting and measuring an amount of protein using an antibody (i.e. “antibody-based methods”) are well known in the art. Non-limiting examples include an ELISA, a sandwich immunoassay, a radioimmunoassay, an immunoblot or Western blot, flow cytometry, immunohistochemistry, and an array.

[0061] In general, an antibody-based method of detecting and measuring an amount of MIOX comprises contacting some of the sample, or all of the sample, comprising MIOX with an anti-MIOX antibody under conditions effective to allow for formation of a complex between the antibody and the MIOX protein. Typically, the entire sample is not needed, allowing one skilled in the art to repeatedly detect and measure the amount of MIOX in the sample. The method may occur in solution, or the antibody or MIOX protein comprising the sample may be immobilized on a solid surface. Non-limiting examples of suitable surfaces may include microtitre plates, test tubes, slides,

beads, resins, and other polymers. Attachment to the substrate may occur in a wide variety of ways, as will be appreciated by those in the art. For example, the substrate and the antibody may be derivatized with chemical functional groups for subsequent attachment of the two. For example, the substrate may be derivatized with a chemical functional group including, but not limited to, amino groups, carboxyl groups, oxo groups or thiol groups. Using these functional groups, the antibody may be attached directly using the functional groups or indirectly using linkers. An anti-MIOX antibody may also be attached to the substrate non-covalently. For example, a biotinylated anti-MIOX antibody may be prepared, which may bind to surfaces covalently coated with streptavidin, resulting in attachment. Alternatively, an antibody may be synthesized on the surface using techniques such as photopolymerization and photolithography.

[0062] Contacting the sample with an antibody under effective conditions for a period of time sufficient to allow formation of a complex generally involves adding the anti-MIOX antibody composition to the sample and incubating the mixture for a period of time long enough for the anti-MIOX antibody to bind to any antigen present. After this time, the complex will be washed and the complex may be detected and the amount measured by any method well known in the art. Methods of detecting and measuring an amount of an antibody-polypeptide complex are generally based on the detection of a label or marker. The term "label", as used herein, refers to any substance attached to an antibody, or other substrate material, in which the substance is detectable by a detection method. Non-limiting examples of suitable labels include luminescent molecules, chemiluminescent molecules, fluorochromes, fluorescent quenching agents, colored molecules, radioisotopes, scintillants, biotin, avidin, streptavidin, protein A, protein G, antibodies or fragments thereof, polyhistidine, Ni²⁺, Flag tags, myc tags, heavy metals, and enzymes (including alkaline phosphatase, peroxidase, glucose oxidase, and luciferase). Methods of detecting and measuring an amount of an antibody-polypeptide complex based on the detection of a label or marker are well known in the art.

[0063] In some embodiments, an antibody-based method is an immunoassay. Immunoassays can be run in a number of different formats. Generally speaking,

immunoassays can be divided into two categories: competitive immunoassays and non-competitive immunoassays. In a competitive immunoassay, an unlabeled analyte in a sample competes with labeled analyte to bind an antibody. Unbound analyte is washed away and the bound analyte is measured. In a non-competitive immunoassay, the antibody is labeled, not the analyte. Non-competitive immunoassays may use one antibody (e.g. the capture antibody is labeled) or more than one antibody (e.g. at least one capture antibody which is unlabeled and at least one “capping” or detection antibody which is labeled.) Suitable labels are described above.

[0064] In other embodiments, an antibody-based method is an immunoblot or Western blot. In yet other embodiments, an antibody-based method is flow cytometry.

[0065] In different embodiments, an antibody-based method is immunohistochemistry (IHC). IHC uses an antibody to detect and quantify antigens in intact tissue samples. The tissue samples may be fresh-frozen and/or formalin-fixed, paraffin-embedded (or plastic-embedded) tissue blocks prepared for study by IHC. Methods of preparing tissue block for study by IHC, as well as methods of performing IHC are well known in the art.

[0066] In alternative embodiments, an antibody-based method is an array. An array comprises at least one address, wherein at least one address of the array has disposed thereon an anti-MIOX antibody. Arrays may comprise from about 1 to about several hundred thousand addresses. Several substrates suitable for the construction of arrays are known in the art, and one skilled in the art will appreciate that other substrates may become available as the art progresses. Suitable substrates are also described above. In some embodiments, the array comprises at least one anti-MIOX antibody attached to the substrate is located at one or more spatially defined addresses of the array. For example, an array may comprise at least one, at least two, at least three, at least four, or at least five anti-MIOX antibodies, each antibody recognizing the same or different epitope MIOX epitope, and each antibody may be at one, two, three, four, five, six, seven, eight, nine, ten or more spatially defined addresses.

[0067] In a preferred embodiment, a method for detecting MIOX and/or measuring the amount of MIOX in a biological sample is an immunoassay comprising at

least one capture antibody and at least one capping antibody, wherein each antibody is an isolated anti-MIOX antibody and the capping antibody is attached to label. For example, an immunoassay may comprise at least one, at least two, at least three, at least four, or at least five capture antibodies, and at least one, at least two, at least three, at least four, or at least five capping antibodies. The capture antibody and the capping antibody may recognize the same MIOX epitope or, alternatively, the capture antibody and the capping antibody may each recognize a different MIOX epitope. When more than one capture antibody is used, the use of at least two antibodies that recognize distinct MIOX epitopes may increase the sensitivity of the assay. Non-limiting examples of suitable capture antibodies and suitable capping antibodies include the antibodies disclosed in **Table B**, as well as antibodies that specifically bind MIOX and recognize an epitope within an amino acid sequence selected from the group consisting of SEQ ID NO: 21 and SEQ ID NO:22. In some embodiments, a capture antibody is an isolated antibody that specifically binds MIOX and is listed in **Table B**. In other embodiments, a capping antibody is an isolated antibody that specifically binds MIOX and is listed in **Table B**. In still other embodiments, a capture antibody and a capping antibody are each an isolated antibody that specifically binds MIOX and are independently selected from the group consisting of the antibodies listed in **Table B**. In different embodiments, a capture antibody is an isolated antibody that specifically binds MIOX and recognizes an epitope within a sequence selected from the group consisting of SEQ ID NO: 21 and SEQ ID NO:22. In still different embodiments, a capping antibody is an isolated antibody that specifically binds MIOX and recognizes an epitope within a sequence selected from the group consisting of SEQ ID NO: 21 and SEQ ID NO:22.

[0068] In an exemplary embodiment, a capture antibody is an isolated antibody that specifically binds MIOX and recognizes an epitope within SEQ ID NO: 21 and a capping antibody is an isolated antibody that specifically binds MIOX and recognizes an epitope within SEQ ID NO: 22. In another exemplary embodiment, a capture antibody is an isolated antibody that specifically binds MIOX and recognizes an epitope within SEQ ID NO: 22 and a capping antibody is an isolated antibody that specifically binds MIOX and recognizes an epitope within SEQ ID NO: 21.

(b) Methods to detect renal injury in a subject

[0069] In aspect, the invention provides means to classify a subject based on the amount of MIOX measured in a biological sample obtained from the subject. The method generally comprises (i) obtaining a biological sample from a subject and measuring the amount of MIOX in the sample using an antibody that specifically binds MIOX, (ii) comparing the amount of MIOX in the sample to a reference value, and (iii) classifying the subject as having a high or low amount of MIOX based on the amount of MIOX measured in the sample. Methods for obtaining a biological sample from a subject and measuring the amount of MIOX in the sample using an antibody that specifically binds MIOX are detailed above and further described in the Examples. In a preferred embodiment, the biological sample is biological fluid selected from the group consisting of blood, plasma, serum, and urine.

[0070] Any suitable reference value known in the art may be used. For example, a suitable reference value may be the amount of MIOX in a biological fluid sample obtained from a subject or group of subjects of the same species that has normal renal function. In another example, a suitable reference value may be the amount of MIOX in biological fluid sample obtained from a subject or group of subjects of the same species that has renal injury as measured by creatinine or other non-specific biomarker of renal function but that has proximal tubule injury. In another example, a suitable reference value may be a measurement of the amount of MIOX in a reference sample obtained from the same subject. The reference sample comprises the same type of biological fluid as the test sample, and may or may not be obtained from the subject when renal function was normal. A skilled artisan will appreciate that it is not always possible or desirable to obtain a reference sample from a subject when the subject is otherwise healthy. For example, in an acute setting, a reference sample may be the first sample obtained from the subject at presentation. In another example, when monitoring the effectiveness of a therapy, a reference sample may be a sample obtained from a subject before therapy began.

[0071] According to the invention, a subject may be classified based on the amount of MIOX measured in the sample. Classifying a subject based on the amount of

MIOX measured in a sample of biological fluid obtained from the subject may be used to identify subjects with renal injury. The term “renal injury” is described in detail below. Generally speaking, a subject may be classified as having a high or low amount of MIOX compared to a reference value, wherein a high amount of MIOX is an amount above the reference value and a low amount is an amount equal to or below the reference value. In preferred embodiments, to classify a subject as having a high amount of MIOX, the amount of MIOX in the sample compared to the reference value may be at least 5% greater. For example, the amount of MIOX in the sample may be at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% greater than the reference value. In other embodiments, the amount of MIOX in the sample of biological fluid obtained from the subject compared to the reference value may be increased at least 2-fold. For example, the amount of MIOX in the sample compared to the reference value may be increased at least 2-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 35-fold, at least 40-fold, at least 45-fold, or at least 50-fold.

[0072] In another aspect, the invention provides means to detect renal injury in a subject. As used herein, the term “renal injury” refers to a loss of kidney function. The causes of renal injury known in the art are numerous, and may include, but are not limited to, necrosis, ischemia, vascular damage, exposure to substances that damage the kidney such as toxins, intravenous contrast, antibiotics, pigments, and LPS, obstruction of the urinary tract, and trauma or crush injury to the kidney. Further by “renal injury” is meant acute kidney injury, as defined according to the Acute Kidney Injury Network criteria (see Metha et al. *Cri Care* 2007). Biomarkers of kidney function are well known in the art. Non-limiting examples of biomarkers of renal injury include increased proteinuria, a rise in serum creatinine, a reduction in urine output, and an increase in blood urea nitrogen. Evidence of renal injury may also be obtained histologically. Applicants have also discovered that increased MIOX in a biological fluid is also a biomarker of renal injury. In a preferred embodiment, the invention provides means to detect renal injury directly or indirectly associated with proximal tubule injury.

[0073] In an aspect, the invention provides means to detect proximal tubule injury in a subject. The proximal tubule is the portion of the duct system of the nephron of the kidney which leads from Bowman's capsule to the loop of Henle. The causes of proximal tube injury are known in the art and may include, but are not limited to, necrosis, ischemia, vascular damage, exposure to substances that damage the kidney such as toxins, antibiotics, pigments, and LPS, obstruction of the urinary tract, and trauma or crush injury to the kidney. Applicants have discovered that increased MIOX in a biological fluid is also a biomarker of proximal tubule injury. Non-specific biomarkers of renal injury, such as serum creatinine or other non-specific markers known in the art, may or may not indicate the presence of proximal tubule cell damage. In a preferred embodiment, the invention provides means to detect renal injury directly or indirectly associated with proximal tubule cell damage.

[0074] For each aspect, the method generally comprises (i) obtaining a biological sample from a subject, (ii) measuring the amount of MIOX in the sample using an antibody that specifically binds MIOX, and (iii) comparing the amount of MIOX in the sample to a reference value. A greater amount of MIOX in the sample compared to the reference value indicates renal injury, proximal tubular injury, proximal tubular cell death, protein loss from the proximal tubules, or a combination thereof. The amount of MIOX may be a qualitative, a semi-quantitative or quantitative measurement. Suitable anti-MIOX antibodies are described above, as are methods for measuring the amount of MIOX in a biological sample. In a preferred embodiment, the biological sample is biological fluid selected from the group consisting of blood, plasma, serum, and urine.

Table C. Sequence listings

SEQ ID NO:	Description	SEQUENCE
1	mAb 01D10 LC CDR1	SGNIHNYLA
2	mAb 01D10 LC CDR2	NAKTLADGVPS
3	mAb 01D10 LC CDR3	QHFWSIPFT
4	mAb 01D10 HC CDR1	TSYYIH

5	mAb 01D10 HC CDR2	WIYPGSGNSKYNE
6	mAb 01D10 HC CDR3	YYCARDGST
7	mAb 12H06 LC CDR1	SKSVSTSGY
8	mAb 12H06 LC CDR2	LLIYLASNLES
9	mAb 12H06 LC CDR3	TYYCQHSRE
10	mAb 12H06 HC CDR1	TSYWMH
11	mAb 12H06 HC CDR2	LIDPSDSYTNYNQ
12	mAb 12H06 HC CDR3	YYCVRYYH
13	mAb 01D10 LC variable domain	DIQMTQSPASLSASVGETVTITCRTSGNIHNYLAWYQQKQKQSPQLLVYNAKTLADGVPSRFSGSG SGTQYSLKINSLQPEDFGSYQCQHFWSIPFTFGSGTKLEIKRAD
14	mAb 01D10 HC variable domain	QVQLQQSGPELVKPGASVKISCKASGYSTSYIHWVKQRPGQGLEWIGWIYPGSGNSKYNEKFKG KATLTADTSSSTAYMQLSSLTSEDSAVYYCARDGSTYNWNFDVWGTGTTVTVSSAKTTPPSVYP
15	mAb 12H06 LC variable domain	DIVVTQSPASFAVSLGQRATISCRASKSVSTSGYSINWYQQKPGQPPKLLIYLASNLESVGPARGFSG SGSGTDFTLNIHPVEEEDAATYYCQHSRELPLTFGAGTRLELK
16	mAb 12H06 HC variable domain	QVQLQQPGAELVRPGTSVKLSCKASGYFTSYWMHWVKQRPGQGLEWIGLIDPSDSYTNYNQKFK GKATLTVDTSSSTASMQLSSLTSEDSAVYYCVRYYHSSYFFAYWGQGLVTVSSAKTTPPSVYP
17	mAb 01D10 LC variable domain	GACATCCAGATGACCCAGTCTCCAGCCTCCCTATCTGCATCTGTGGGAGAACTGTCACCATCA CATGTCGAACAAGTGGGAATATTCACAATATTTAGCATGGTATCAGCAGAAACAGGGAAAATCT CCTCAGCTCCTGGTCTATAATGCAAAAACCTTAGCAGATGGTGTCCATCAAGGTTCAAGTGGCA GTGGATCAGGAACACAATATCTCTCAAGATCAACAGCCTGCAACCTGAAGATTTGGGAGTTAT TACTGTCAACATTTTTGGAGTATCCATTACGTTCCGGCTCGGGGACAAAGTTGAAAATAAACG GGCTGAT
18	mAb 01D10 HC variable domain	CAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCC TGCAAGGCTTCTGGCTACAGCTTCAACAAGCTACTATACACTGGGTGAAGCAGAGGCCTGGAC AGGGACTTGAGTGGATTGGATGGATTTATCCTGGAAGTGGTAATTCTAAGTACAATGAGAAGTTC AAGGGCAAGGCCACACTGACGGCAGACACATCCTCCAGTACTGCCTACATGCAACTCAGCAGC CTAACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGAGACGGTAGTACCTACAACCTGGAAC TCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCCTCAGCCAAAACAACACCCCCATCAG TCTATCCA
19	mAb 12H06 LC variable domain	GACATTGTGGTGACACAGTCTCCTGCTTCCTTGCTGTATCTCTGGGGCAGAGGGCCACCATCT CATGCAGGGCCAGCAAAAGTGTGAGTACATCTGGCTATAGTTATATAAACTGGTACCAACAGAA ACCAGGACAGCCACCAAACTGCTCATCTATCTTGCATCCAACCTAGAACTCTGGGGTCCCTGCC AGGTTCAAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAG GATGCTGCAACCTAITACTGTGACACAGTAGGGAGCTTCCTCTACGTTCCGGTCTGGGACCA GGCTGGAGCTGAAA
20	mAb 12H06 HC variable domain	CAGGTCCAAGTGCAGCAGCCTGGGGCTGAACTGGTGAAGCCTGGGACTTCAGTGAATGTCC TGCAAGGCTTCTGGCTACACCTTACCAGCTACTGGATGCACTGGGTAAACAGAGGCCTGGAC AAGGCCTTGAGTGGATCGGTCTGATTGATCCTTCTGATAGTTATACTAACTACAATCAAAAGTTC AAGGGCAAGGCCACATTGACTGTAGACACATCCTCCAGCACAGCCTCCATGCAACTCAGCAGC CTGACATCTGAGGACTCTGCGGTCTATTACTGTGTAAGAACTTACTACCATAGTAGTACTTCTT TGCTTACTGGGGCAAGGGACTCTGGTCACTGTCTCTTACGCCAAAACAACACCCCCATCAGTC TATCCA
21	12H06 human MIOX epitope	RPYYQGLIDKYC
22	01D10 human MIOX epitope	PSLVYRPDVEDPEV
23	N-terminus of MIOX	GSPEFKVTVG

24	N-terminus of GST	MSPILGYWKI
25	Epitope of rabbit polyclonal antibody R9544	MKVTVGPDPSPVYRPDVDPEVAKDKASFR
26	Epitope of rabbit polyclonal antibody R9544	GLVDESDPDVDFPNSF
27	Epitope of rabbit polyclonal antibody R9544	DSTFQDNPDLDQPR
28	Epitope of rabbit polyclonal antibody R9544	QGLIDKYCPG
29	Amino acid sequence of human MIOX	MKVTVGPDPSPVYRPDVDPEVAKDKASFRN YTSGPLLDRV FTTYKLMHHTH QTVDFVRSKH AQFGGFSYKK MTVMEAVDLL DGLVDESDPD VDFPNSFHAF QTAEGIRKAH PDKDWFHLVG LLHDLGKVLALFGEPQAWAGDTFPVGCPRQASVVFCDSTFQDNPDLDQDPYRSTELGMYQ PHCGLDRVLMWSWGHDEYMYQVMKFNKFSLPPEAFYMIRFHSFYWPWHTGRDYQQLCSQQDL AMLPWVREFNKFDFLYTKCPDLPDVKLRPYQQGLIDKYCPGILSW
30	Portion of MIOX sequence, Mouse or Rat	PSLVYRPDVDPEM
31	Portion of MIOX sequence, Pig or Cat	PSLVYRPDVDPEA
32	Portion of MIOX sequence, Guinea Pig	PSLIYRPDMDPEM
33	Portion of MIOX sequence, Ground Squirrel	PSLVYRPDVGTEA
34	Portion of MIOX sequence, Dog	PSLVYRPDMDPEK

EXAMPLES

[0075] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the invention. Those of skill in the art should, however, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention, therefore all matter set forth or shown in the accompanying examples and drawings is to be interpreted as illustrative and not in a limiting sense

[0076] Antibodies specific for the MIOX protein were generated as described below in Example 2 and in the Methods. Specifically, two hybridomas were generated and two antibodies were obtained from the hybridomas.

Example 1: Identification of myo-inositol oxygenase as a renal specific biomarker.

[0077] We sought to identify mouse genes that were expressed in the kidney by a factor of at least 10-fold compared with other tissues. Previous studies by Laterza, et al. dissected brain, liver, spleen, kidney, skeletal muscle, lung, pancreas, heart, and small intestine from 3 (2 male and 1 female) C57Bl/6 mice (Laterza et al. Clin Chem. 2006;52:1713). This previously generated data was mined for genes that had mean signal intensity of >10,000, were expressed at >10-fold amounts in the kidney relative to the other tissues, and were expressed in the renal proximal tubule. Using this strategy, *Miox* was identified as a renal specific, abundant gene (**FIG. 1A**). The *Miox* gene encodes the protein *myo*-inositol oxygenase (Miox). In order to confirm the tissue specific nature of the human homolog of Miox, hereinafter abbreviated MIOX, human tissue homogenates from liver, brain, lung, kidney, spleen, testis, ovary, heart, and pancreas were probed using an anti-MIOX rabbit polyclonal antibody. Consistent with the mouse gene profiling data, MIOX protein was only detected in human kidney homogenate (**FIG. 1B**) (Gaut JP, et al. Clin Chem. 2014:60(5):747-57).

Example 2: Characterization of anti-MIOX antibodies.

[0078] Rabbit polyclonal and mouse monoclonal anti-MIOX antibodies were generated using recombinant GST-tagged MIOX as antigen. To confirm the identity of recombinant GST-MIOX, the protein was first cleaved into GST and MIOX with thrombin. The cleaved proteins were separated by use of SDS-PAGE and subjected to Edman sequencing (**FIG. 3A**). The protein migrating between 26 and 37 kDa gave a sequence of GSPEFKVTVG (SEQ ID NO:23) corresponding to the N-terminus of MIOX. The protein near 26 kDa gave a sequence of MSPILGYWKI (SEQ ID NO:24) corresponding to the N-terminus of *S. japonicum* GST. Both monoclonal antibodies were isotyped and found to be IgG_{2bκ}. Western blots were used to confirm the antibodies' ability to recognize recombinant MIOX and endogenous MIOX present in normal human kidney homogenate (**FIG. 3A**).

The polyclonal and monoclonal antibodies recognized a protein with molecular mass between 26 and 37 kDa that comigrated with the recombinant MIOX protein (**FIG. 3A**). These results are consistent with the expected molecular weight of MIOX, 33 kDa.

[0079] The cross-species immunoreactivity of the anti-MIOX monoclonal antibodies was investigated (**FIG. 3D,E**). Human, mouse, and rat kidney homogenates were separately probed with both monoclonal anti-MIOX antibodies. All three homogenates showed immunoreactivity at the expected molecular weight of endogenous MIOX.

[0080] The linear epitopes of the anti-MIOX antibodies were determined by use of spot-peptide membrane arrays containing the full length amino acid sequence of MIOX. The two mouse monoclonal antibodies mapped to opposite ends of the MIOX sequence (**FIG. 3B**). The antibody designated 01D10 mapped to the N-terminal sequence of MIOX (**FIG. 3C**). The peptide spots were decoded to reveal the sequence P9-V21. The mouse monoclonal antibody designated 12H06 mapped to the C-terminal region of MIOX (**FIG. 3C**). The peptide spots were decoded to reveal the epitope sequence R268-C279. Human MIOX showed 89.8% homology to mouse Miox and 90.5% homology to rat Miox. The peptide epitope recognized by the 12H06 mouse monoclonal antibody was 100% identical to the corresponding mouse and rat Miox peptide sequence. The peptide epitope recognized by the 01D10 mouse monoclonal antibody was 92% identical to the corresponding mouse and rat Miox peptide sequence. The epitope recognized by the 01D10 mouse monoclonal antibody differed by 1 amino acid: the valine at amino acid position 21 is replaced by a methionine in mouse Miox. The rabbit anti-MIOX polyclonal antibody R9544 demonstrated 5 regions of intense staining, a finding consistent with the polyclonal nature of this antibody (**FIG. 3C**). Each monoclonal epitope sequence was validated for its uniqueness in a nonredundant *Homo sapiens* database by use of BLAST. A critical output parameter from BLAST is the expected value (E value). The E value is a measure of the chance that a random alignment from the probed database would produce the same normalized score. On the basis of the E value, there is a <1 in >1 000 000 chance that the epitope sequences could be randomly found in the database (data not shown). The lowest E value of a non-MIOX protein was 2.3,

compared to a MIOX E value of 1×10^{-6} , indicating the highly specific nature of the antibody epitopes. Individual peptides corresponding to the mapped epitopes for both monoclonal antibodies were produced. Preincubation by use of the N-terminal peptide epitope, but not the C-terminal peptide epitope, inhibited binding of the 01D10 mouse monoclonal anti-MIOX antibody to a MIOX spot-peptide array (**FIG. 4A**). Similarly, preincubation by use of the C-terminal peptide epitope, but not the N-terminal peptide epitope, inhibited binding of the 12H06 mouse monoclonal anti-MIOX antibody to a MIOX spot-peptide array (**FIG. 4B**).

Example 3: Immunohistochemical analysis of MIOX in human kidney.

[0081] Human kidney tissues were obtained from the uninvolved portions of partial nephrectomy specimens from patients with renal cell carcinoma. Single formalin-fixed paraffin embedded sections were stained with rabbit polyclonal anti-MIOX antibody. Consistent with previous studies, the MIOX protein showed strong immunoreactivity in the proximal tubules (**FIG. 2A,B**) (Hu E, et al. *Am J Physiol Renal Physiol.* 2000;279:F426; Arner RJ et al. *Biochem Biophys Res Commun* 2006;339:816).

Example 4: MIOX immunoassay.

[0082] The mouse monoclonal antibodies were optimized for use in a sandwich immunoassay. The monoclonal antibody designated 12H06 was used as a capture antibody and biotinylated monoclonal antibody 01D10 was used as a capping antibody. The limit of detection, defined as a signal-to-noise ratio of 2 relative to background, was 115 (55) pg/mL [n = 13, mean (SD)] (**Table 1**). Human plasma samples stored at 4 °C or -80 °C for 10 days showed no significant difference in MIOX concentration [absolute mean % difference = 7.4% (4.0%), mean % difference = -0.4% (9.4%); n = 4]. The interassay coefficient of variation (CV) was determined by calculating the median concentration of 3 samples on 3 separate days. The interassay CV was 15.2% (3.4%) [mean MIOX concentration 5.6 (0.7) ng/mL, n=9]. All samples underwent 2 freeze-thaw cycles. The intra-assay CV, determined by use of 19 plasma samples with a mean MIOX concentration of 21.2 ng/mL, range 1.7–48.2 ng/mL, was 7.9% (5.2%). GST-MIOX spiked into human

heparinized plasma demonstrated 94% (19%) recovery of the expected signal ($n = 8$). The MIOX immunoassay demonstrated dilutional linearity recovery of 109% (12%) ($n = 9$).

Table 1. MIOX immunoassay performance characteristics.

<i>Interassay CV</i>	15.2 ± 3.4%, $n=9$
<i>Intraassay CV</i>	7.2 ± 5.2%, $n=19$
<i>LOD (pg/mL)</i>	115 ± 55, $n=13$
<i>Spike/recovery</i>	94 ± 19%, $n=8$
<i>Dilutional linearity recovery</i>	109 ± 12%, $n=9$
Abbreviations: CV – coefficient of variation; LOD – limit of detection	

Example 5: Mouse AKI Model.

[0083] A mouse model of kidney ischemia-reperfusion injury, which mimics clinical AKI, was used as a proof of concept study to assess the specificity and sensitivity of MIOX for AKI. Animals were subjected to bilateral renal artery clamping for 30 minutes to induce AKI. Blood and urine MIOX levels are correlated with histologic evidence of kidney injury, serum creatinine, and blood urea nitrogen at multiple time points. Histologic staining was performed according to standard procedures, as was measurement of blood urea nitrogen. **FIG. 5D** depicts blood urea nitrogen levels at baseline and 24h after injury. Miox was not detected in the serum of normal or sham-operated mice 24 h postoperatively (**FIG. 5A**). In contrast, Miox was markedly increased in the serum of mice 24 h after 30 min of bilateral ischemia reperfusion injury (**FIG. 5A**). Histologic examination of kidneys from sham-operated animals showed no evidence of tubular necrosis (**FIG. 5B**). In contrast, histologic examination revealed significant tubular necrosis in the kidneys of the experimental mice 24 h after injury (**FIG. 5C**).

Example 6: Analysis of plasma from acute kidney injury patients.

[0084] Patients in an intensive care unit (ICU) were screened for AKI, defined according to the AKIN criteria. Patients were screened for plasma creatinine increases of at least 1.5 times baseline or an absolute increase of 0.3 mg/dL (0.027 mmol/L) over

a 1-3 day time period. Once a patient was identified who had an increase in plasma creatinine, remnant heparin plasma samples were collected from the Barnes Hospital Clinical Chemistry Laboratory at the time of the plasma creatinine increase and 1–3 days before the plasma creatinine increase (time 0). Plasma creatinine increased a mean (SE) of 54 (3.8) h (n = 33; time 54) after the time 0 sample. The patient characteristics are summarized in **Table 2**. Oliguria was defined according to standard criteria as <0.5 mL/kg/h for at least 6 hours (Mehta et al. Crit Care 2007). A total of 42 patients fulfilled criteria for at least stage I AKI, defined as a relative increase in plasma creatinine of 50%, an absolute increase in plasma creatinine of 0.3 mg/dL (0.027 mmol/L), or a decrease in urine output to <0.5 mL/kg/h for at least 6 h. Of the 42 patients with AKI, 33 had increases in plasma creatinine of at least 1.5 times baseline. Nine patients had a urine output of <0.5 mL/kg/h for at least 6 h without a change in plasma creatinine. Seventeen hospitalized or critically ill patients who did not meet criteria for AKI served as controls. There was no significant difference in age between the patient groups. There was a greater proportion of male patients within the AKI group. Plasma MIOX was measured in critically ill patients with AKI at time 0 h (n = 42) and time 54 h (n = 37); the mean time plasma creatinine increased (**FIG. 7A**). Samples were not available at the time of plasma creatinine increase for 5 patients. Plasma MIOX was significantly increased in patients with AKI at time 0 [12.4 (4.3) ng/mL] and at time 54 [10.1 (5.3) ng/mL] relative to controls [0.5 (0.3) ng/mL; $P = 0.002$] (**FIG. 7B**). Patients with oliguric AKI had significantly higher plasma MIOX values at time 0 [20.2 (7.5) ng/mL, n = 23] and time 54 [17.1 (11.0) ng/mL, n = 17] compared with controls ($P < 0.05$) (Fig. 6). Significantly higher plasma MIOX concentrations were observed in patients with dialysis requiring AKI at time 0 [8.2 (3.5) ng/mL, n = 5] and time 54 [8.2 (3.1) ng/mL, n = 5] compared with controls ($P < 0.05$) (**FIG. 8A-D**). All plasma MIOX concentrations were determined before initiation of dialysis. The increase in plasma MIOX preceded the increase in plasma creatinine by a mean of 54.3 (3.8) h (n = 33).

[0085] Radiographic evidence of unilateral renal ischemia was available for one patient. Patient number 62 presented to the ER with chest pain. A computed tomography (CT) scan was ordered and an aortic dissection was diagnosed (**FIG. 6A**). This CT scan also revealed mal-perfusion of the right kidney, consistent with renal

ischemia. The plasma MIOX value at the time of admission was 59.2 ng/mL. 33 hours later, the plasma MIOX value decreased to 17.0 ng/mL (**FIG. 6C**). In contrast, the serum creatinine at the time of admission was 1.56 mg/dL. No prior laboratory values were available for comparison. 33 hours later, the serum creatinine increased to 3.02 mg/dL (**FIG. 6B**).

Table 2. Patient characteristics.

	Control; No AKI (n=17)	AKI (n=42)	Non-oliguric AKI (n=14)	Oliguric AKI (n=23)	Dialysis-requiring AKI (n=5)
Age (years)	58 ± 4	58 ± 2	63 ± 4	56 ± 2	57 ± 8
M:F	8:9	24:18	7:7	14:9	3:2
Race					
Caucasian	14/17 (82%)	31/42 (74%)	11/14 (79%)	16/23 (70%)	4/5 (80%)
African American	2/17 (12%)	10/42 (24%)	2/14 (14%)	7/23 (30%)	1/5 (20%)
Hispanic	0	1/42 (2%)	1/14 (7%)	0	0
Unknown	1/17 (6%)	0	0	0	0
Peak SCr (mg/dL)	0.88 ± 0.08	2.03 ± 0.17 ^a	1.95 ± 0.12 ^a	1.81 ± 0.19 ^a	3.28 ± 0.78 ^a
Peak BUN (mg/dL)	16 ± 2	36 ± 3 ^a	38 ± 4 ^a	31 ± 2 ^a	57 ± 20 ^a
^a p<0.005 compared with the control group (Kruskal-Wallis with Dunn correction for post hoc tests)					
AKI – acute kidney injury; SCr – serum creatinine; BUN – blood urea nitrogen.					

Discussion for Examples 1-6

[0086] An ideal acute kidney injury biomarker should be kidney specific, rapidly detectable following injury, correlate with the degree of tissue damage, and be easily measured. A variety of approaches have been used to identify such a biomarker. In the current study, we first sought to identify kidney specific genes. Since the proximal tubule is the major site of ischemic damage, genes specific to the proximal tubule were targeted. Using differential gene expression profiling, MIOX was identified as a renal specific proximal tubule gene. The tissue specificity was confirmed using Western blot. MIOX was localized to the proximal tubule of the kidney using immunohistochemistry. Mouse monoclonal anti-MIOX antibodies were developed and characterized. These monoclonal antibodies were optimized for use in a sandwich immunoassay to quantify

MIOX in plasma. This assay was used to investigate the utility of MIOX as a biomarker of human acute kidney injury. Mice subjected to bilateral renal ischemia-reperfusion showed increased plasma MIOX 24 h postinjury. Critically ill patients with acute kidney injury showed markedly elevated plasma MIOX compared to control patients without acute kidney injury. Serum MIOX was highest in patients with oliguric and dialysis-requiring acute kidney injury. Importantly, the elevation in plasma MIOX occurred approximately 2 days prior to the elevation in plasma creatinine.

[0087] MIOX is a unique, renal specific enzyme that catalyzes the first committed step in *myo*-inositol metabolism (Arner RJ, et al. *Biochem J.* 2001;360:313-320; Thorsell AG, et al. *J Biol Chem.* 2008;283:15209-15216). The MIOX mRNA transcript is reportedly downregulated in a rat model of ischemic acute kidney injury (Hu et al. *Am J Physiol Renal Physiol* 2000;279:F426-F439). In this study, the authors hypothesized that loss of MIOX mRNA was directly related to the degree of necrosis observed following renal ischemia. In the current study, demonstration of increased plasma MIOX following acute kidney injury may also be related to necrosis of the proximal tubule, although secretion cannot be ruled out.

[0088] It is noteworthy that MIOX was not detected in the plasma of all patients with acute kidney injury as defined using the AKIN criteria (Mehta et al.). Because the timing of renal injury was unknown in this patient population, it is possible that an increase in plasma MIOX may have occurred before or after samples were obtained. Plasma creatinine is a nonspecific biomarker of renal injury, so it is possible that a subset of patients developed increased plasma creatinine in the absence of proximal tubule cell damage.

[0089] Other proteins have been investigated as potential kidney injury biomarkers. Previous studies have demonstrated that α -glutathione-S-transferase (α -GST), liver type fatty acid-binding protein 1 (FABP1) and *N*-acetyl- β -D-glucosaminidase (NAG) are detectable in urine following renal injury (Noiri E et al. *Am J Physiol Renal Physiol* 2009;296:F669-F679; Westhuyzen J et al. *Nephrol Dial Transplant* 2003;18:543-555). However, none of these has yet translated into clinical use. In contrast to these biomarkers, MIOX is a kidney specific protein. MIOX is also an

endogenous kidney protein. Therefore, it may be released more rapidly than the inducible biomarkers KIM-1, NGAL, and FABP1. Measuring these analytes together may provide more detailed information regarding the timing of renal injury. Interestingly, MIOX did not appear to signal non-oliguric kidney injury in this retrospective study. It will be important to confirm this result in a prospective study. Nonetheless, it is most likely that a panel of biomarkers will be necessary to accurately detect AKI, determine severity, and localize the portion of the nephron injured in a given clinical scenario.

[0090] There are several limitations to this study. The human samples were collected in a retrospective manner from critically ill and hospitalized patients. The study population was screened for patients with clinical evidence of acute kidney injury and is therefore not an accurate representation of all critically ill patients. Since these samples were obtained retrospectively, they were not immediately frozen following collection. Rather, the samples were stored at 4°C for 1-7 days prior to aliquoting and freezing. Although the MIOX immunoassay does not appear to be significantly affected by storing plasma for one week at 4°C, it is important to note that the samples were not all handled identically. This may have introduced artifact into the analysis. Previous studies confirmed the kidney-specific nature of MIOX. However, it is unknown whether MIOX expression patterns may change in other tissues following AKI or multi-organ failure. Additional studies are necessary to investigate the tissue expression profile of MIOX in these settings to explore the renal-specific nature of its origin.

[0091] In conclusion, we developed an immunoassay to quantify the kidney specific protein MIOX in human plasma. We demonstrated that plasma MIOX was elevated in animals and critically ill patients with acute kidney injury. In critically ill patients, MIOX increased approximately 2 days prior to the increase in plasma creatinine, potentially opening a therapeutic window. Additional studies are warranted to further investigate the potential of MIOX as an early biomarker of acute kidney injury.

Methods for Examples 1-6

[0092] *Gene array analysis.* We identified kidney-specific genes according to methods described previously (*Laterza et al*). Briefly, brain, liver, spleen, kidney, skeletal

muscle, lung, pancreas, heart, and small intestine were dissected from 3 C57Bl/6 mice and snap frozen in liquid nitrogen. Total RNA was isolated, converted into biotinylated complementary RNA (cRNA), fragmented, and applied to mouse MU75A (version 1) Genechip arrays (Affymetrix). The fluorescence intensity was scaled to 1500, and the mean difference values were calculated with Affymetrix software by measuring the difference between the perfect match and mismatch oligonucleotides. We mined these data for genes with mean difference values >10 000 in the kidney, expressed at >10-fold amounts in the kidney relative to other tissues, and expressed in the proximal tubule.

[0093] *Generation and purification of recombinant MIOX* The nucleotide sequence for MIOX was inserted into a pGEX vector for production in *Escherichia coli*. Recombinant MIOX was purified using immobilized glutathione from Pierce according to manufacturer's instructions. Purified protein was analyzed using gel electrophoresis to confirm purity. Concentrations were determined using absorbance at 280 nm with calculated extinction coefficients from the sequence plus the GST construct or using N-terminal Edman sequencing. MIOX and GST sequences were obtained from the Swiss-Prot website (<http://www.expasy.org/sprout>). Recombinant GST-MIOX (absent the N-terminal methionine initiator) was cleaved with thrombin to obtain recombinant MIOX (rMIOX) protein devoid of GST. Cleaved MIOX contained an N-terminal extension of GSPEF. This material was analyzed using N-terminal Edman sequencing to confirm identity.

[0094] *Anti-MIOX antibodies* Rabbit polyclonal antibodies were produced at Harlan Bioproducts for Science (Madison, WI) using recombinant GST-MIOX as an immunogen. Polyclonal antibodies were purified in two steps. Cross-reacting anti-GST antibodies were first removed from sera with a GST column (#20205, Pierce) according to manufacturer's instructions. Antibodies were then affinity purified as described previously (Crimmins D, et al. *Biotechnol Appl Biochem*. 2010;57:127-38). Mouse monoclonal antibodies were produced at Maine Biotechnology Services, Inc (Portland, ME) using recombinant GST-MIOX as the immunogen and purified from cell culture media using a protein A-agarose column. Purified antibodies were dialyzed against phosphate-buffered saline, pH 7.2 containing 0.05% NaN₃ and quantified using

absorbance at 280 nm. Monoclonal antibodies were typed using Isotyping cassettes from Pierce (#26179). Epitope mapping was performed using ABIMED spot peptide arrays prepared at the MIT Biopolymers facility as described previously (Laterza OF, et al. Clin Chem 2006;52:1713-1721).

[0095] *Western blotting* Normal human kidney homogenate was purchased from G-Biosciences (NLH-04, G-Biosciences). Mouse and rat kidney homogenate was purchased from G-Biosciences, St. Louis, MO. Western blotting was performed as previously described (Laterza OF, et al. Clin Chem 2006;52:1713-1721). Blots were probed with 0.004 mg/mL of the rabbit polyclonal anti-MIOX antibody R9544 or 0.004 mg/mL of either the 01D10 or 12H06 mouse anti-MIOX monoclonal antibody. Where indicated, both monoclonal antibodies were used simultaneously, each at the above concentrations.

[0096] *Immunohistochemistry* Formalin-fixed paraffin embedded human kidney tissue was obtained retrospectively from the Lauren V. Ackerman Laboratory of Surgical Pathology at Barnes Hospital. Samples were obtained from the uninvolved portions of kidneys resected for renal cell carcinoma. Single sections were stained following sodium citrate antigen retrieval using a Ventana autostainer as described previously (Gaut JP et al. Mod Pathol. 2012;Nov 30:epub ahead of print). A final concentration of 5 µg/mL of the rabbit polyclonal anti-MIOX antibody was used.

[0097] *MIOX Immunoassay* A sandwich immunoassay was developed for MIOX using monoclonal antibody 12H06 as capture antibody and biotinylated antibody 01D10 as a capping antibody. Biotinylation of antibody 01D10 was performed using Sulfo-NHS-LC-Biotin (#21338, Pierce) according to manufacturer's instructions. The capture antibody was added to the plate at a concentration of 30 µg/mL. The capping antibody was used at a concentration of 0.33 µg/mL. Non-specific binding was blocked using Pierce Superblock (#37515, Pierce), non-specific mouse immunoglobulin G (#SLM66, Equitech-Bio, Kerryville, TX) and 0.5 mg/mL Tween-20 (#P-1379, Sigma-Aldrich, Saint Louis, MO). Plasma samples, controls, and standards were diluted 1:8 in Superblock, mouse IgG, and Tween-20 prior to analysis. GST-MIOX was serially diluted for construction of a standard curve. The concentration of GST-MIOX was set following

amino acid analysis in triplicate (AAA Services Lab, Inc., Damascus, OR). Streptavidin conjugated to ruthenium (#32AD, MesoScale Discovery, Rockville, MD) was added to samples and detected using a MesoScale Discovery Sector 2400 electrochemiluminescent plate reader. Spike-recovery was determined by adding recombinant MIOX to a final concentration of either 2 ng/mL or 10 ng/mL to control human heparin plasma. Dilutional linearity was evaluated by adding recombinant MIOX to a final concentration of 5 ng/mL to 1:8, 1:16, 1:32, and 1:64 dilutions of control human heparin plasma.

[0098] *Animal Model.* All animal studies were approved by the Animal Studies Committee of Washington University School of Medicine. We used C57Bl/6 mice (3 female and 4 male) ranging in age from 8 to 12 weeks. One week before surgery, serum was collected and frozen at -80°C . Animals were subjected to bilateral renal ischemia for 30 min. Briefly, animals were anesthetized with a mixture of ketamine and xylazine, their body temperature was maintained at 37°C on a heating pad and monitored with a rectal probe throughout surgery, and ischemia was induced by bilateral clamping of renal vascular pedicles for 30 min. Two sham-operated animals (1 male and 1 female) underwent an identical procedure without vascular pedicle clamping. Twenty-four hours after surgery, the animals were killed, serum was collected, and kidneys were perfused with 4% paraformaldehyde and placed in 4% paraformaldehyde (pH 7.4). Serum was stored at -80°C before immunoassay as described above for human plasma. We processed tissues for routine H&E staining according to standard procedures.

[0099] *Human Patients.* All human studies were approved by the internal review board for human studies at Washington University School of Medicine. Patient laboratory data was screened for increases in serum creatinine occurring over a 24-72 hour time period. Patients with chronic kidney disease were not included in the study. Remnant heparin plasma samples were obtained retrospectively from the clinical chemistry laboratory of Barnes Hospital. Plasma samples were obtained before the increase in serum creatinine and at the time of the serum creatinine increase. All plasma samples were aliquoted into 500 μL aliquots and frozen at -80°C prior to analysis. Patient medical records were reviewed for demographic information, urine

output, and diagnosis. Oliguria was defined as a urine output <0.5 mL/kg/h for at least 6 hours.

[0100] *Statistics.* Quantitative data are presented as mean ± SEM. All statistical analyses were performed using GraphPad Prism software. Comparison of individual groups of patients was evaluated using either the Mann-Whitney U Test or t test for non-parametric and parametric data, respectively. Significance was defined as $p < 0.05$.

Example 7: Prospective analysis demonstrating MIOX as an early biomarker of AKI in human cardiac surgery patients

[0101] 700,000 *patients* undergo cardiopulmonary bypass cardiac surgery in the U.S. every year. These patients have a 20-30% incidence of AKI resulting in 40% to 90% mortality. This population is ideal for study since the timing of renal injury is known. Approximately 100 adults scheduled to undergo cardiac surgery involving cardiopulmonary bypass will be enrolled. Pre-operative and post-operative blood and urine MIOX will be correlated with the current clinical standard for renal injury diagnosis (e.g., creatinine, decreased urine output, and initiation of dialysis). MIOX will be detected in blood and urine samples using an anti-MIOX antibody as described earlier. It is anticipated that plasma and urine MIOX will be detectable prior to an appreciable increase in serum creatinine. The increase in plasma and urine MIOX is anticipated to correlate with the severity of renal injury as evidenced by the degree of decrease in urine output and need for dialysis.

[0102] Samples *and* data have been collected for 28 patients. Patient characteristics are listed in **Table 3**. **FIG. 9A-D** shows creatinine levels in 4 patients at baseline, pre-op and at peak. **FIG. 10A-D** shows MIOX levels in 4 patients pre-op and 0, 3, 6, 18 and 24 hours following surgery.

Table 3. Patient Characteristics

Patient information	
Mean Age	65.1
% Female	39% (11/28)

Race	Caucasian – 25, AA – 3
Mean serum creatinine at baseline	1.2 mg/dL
Mean GFR at baseline	64.7 mL/min
Diabetes	20/28
Hypertension	27/28
Congestive heart failure	18/28
Anemia	16/28
Intravenous contrast pre-op	3/28
Mean peak serum creatinine	1.7 mg/dL

CLAIMS

What is claimed is:

1. An isolated antibody, wherein the antibody specifically binds MIOX and recognizes an epitope within an amino acid sequence selected from the group consisting of SEQ ID NO: 21 and SEQ ID NO:22.
2. The isolated antibody of claim 1, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO:14 and SEQ ID NO:16.
3. The isolated antibody of claim 1, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO:13 and SEQ ID NO:15.
4. The isolated antibody of claim 1, wherein the antibody is encoded by a nucleic acid sequence comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20.
5. The isolated antibody of claim 1, wherein the antibody is selected from the group consisting of a single-chain antibody, an antibody fragment, a chimeric antibody, or a humanized antibody.
6. An isolated antibody, wherein the antibody specifically binds MIOX and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6 with zero to two amino acid substitutions.
7. An isolated antibody, wherein the antibody specifically binds MIOX and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12 with zero to two amino acid substitutions.

8. An isolated antibody, wherein the antibody specifically binds MIOX and comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3 with zero to two amino acid substitutions.
9. An isolated antibody, wherein the antibody specifically binds MIOX and comprises a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9 with zero to two amino acid substitutions.
10. An isolated antibody of any of the preceding claims, wherein the antibody is selected from the group consisting of a single-chain antibody, an antibody fragment, a chimeric antibody, or a humanized antibody.
11. An immunoassay comprising at least one isolated antibody of any of the preceding claims.
12. A method for measuring the amount of MIOX in a biological sample, the method comprising (i) obtaining a sample of biological fluid from a subject; and (ii) measuring the amount of MIOX in the sample by immunoassay comprising at least one isolated antibody that specifically binds MIOX, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-12 with zero to two amino acid substitutions.
13. The method of claim 12, wherein the biological sample is a biological fluid selected from the group consisting of blood, plasma, serum and urine.
14. The method of claim 12, wherein measuring the amount of MIOX in the sample by immunoassay comprises a capture antibody and a capping antibody that specifically binds MIOX.
15. The method of claim 14, wherein the capture antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-6 and the capping

- antibody comprises an amino acid selected from the group consisting of SEQ ID NO: 7-12.
16. The method of claim 14, wherein the capture antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7-12 and the capping antibody comprises an amino acid selected from the group consisting of SEQ ID NO: 1-6.
 17. A method for detecting renal injury in a subject, the method comprising (i) obtaining a biological sample from a subject; (ii) measuring the amount of MIOX in the sample by immunoassay using at least one isolated antibody that specifically binds MIOX, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-12 with zero to two amino acid substitutions; and (iii) comparing the amount of MIOX in the sample to a reference value, wherein a greater amount of MIOX in the sample compared to the reference value indicates renal injury in the subject.
 18. The method of claim 17, wherein the renal injury is directly or indirectly associated with proximal tubular injury.
 19. The method of claim 17, wherein the proximal tubular injury is directly or indirectly associated with proximal tubular cell damage.
 20. The method of claim 17, wherein the biological sample is a biological fluid selected from the group consisting of blood, plasma, serum and urine.
 21. The method of claim 17, wherein measuring the amount of MIOX in the sample by immunoassay comprises a capture antibody and a capping antibody that specifically binds MIOX.

22. The method of claim 21, wherein the capture antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-6 and the capping antibody comprises an amino acid selected from the group consisting of SEQ ID NO: 7-12.
23. The method of claim 21, wherein the capture antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7-12 and the capping antibody comprises an amino acid selected from the group consisting of SEQ ID NO: 1-6.
24. A method for detecting proximal tubular injury in a subject, the method comprising (i) obtaining a sample of biological fluid from a subject; (ii) measuring the amount of MIOX in the sample by immunoassay using at least one isolated antibody that specifically binds MIOX, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-12 with zero to two amino acid substitutions; and (iii) comparing the amount of MIOX in the sample to a reference value, wherein a greater amount of MIOX in the sample compared to the reference value indicates proximal tubular injury in the subject.
25. The method of claim 24, wherein the proximal tubular injury is directly or indirectly associated with proximal tubular cell damage.
26. The method of claim 24, wherein the biological sample is a biological fluid selected from the group consisting of blood, plasma, serum and urine.
27. The method of claim 24, wherein measuring the amount of MIOX in the sample by immunoassay comprises a capture antibody and a capping antibody that specifically binds MIOX.
28. The method of claim 27, wherein the capture antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-6 and the capping

antibody comprises an amino acid selected from the group consisting of SEQ ID NO: 7-12.

29. The method of claim 27, wherein the capture antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7-12 and the capping antibody comprises an amino acid selected from the group consisting of SEQ ID NO: 1-6.




FIG. 1





FIG. 2

A



B




FIG. 3

10	20	30	40	50	60
MKVTVGPDP	PS LVYRPD	VAKDKASFRN	YTSGPLLDRV	FTTYKLMH	QTVD
10	20	30	40	50	60
MKVTVGPDP	PS LVYRPD	VAKDKASFR			
70	80	90	100	110	120
AQFGFSYKK	MTVMEAVDLL	DGLVDESDPD	VDFPNSFHAF	QTAEGIRKAH	PKDWFHLVG
		GLVDESDPD	VDFPNSF		
130	140	150	160	170	180
LLHDLGK	LVLA	LFGEQWAVV	GDTFVGC	RP	QASVFC
					DST FQDNPDLQDP R
190	200	210	220	230	240
PHCGLDRVLM	SWGHD	EYMYQ	VMKFNK	FSLP	PEAFYMIRFH
					SFYPWHTGRD
					YQQLCSQQDL
250	260	270	280		
AMLPWVREFN	KFDLYTK	CPD	LPD	VDKLRPY	YQGLIDKYCP
					GILSW
					QGLIDKYCP G
					<u>RPY YQGLIDKYC</u>

FIG. 3C





FIG. 3





FIG. 4








FIG. 5

**FIG. 5D**

A



B




FIG. 6




FIG. 6C






FIG. 7

A



B




FIG. 8






FIG. 8

A



B




FIG. 9






FIG. 9

A

Patient 001



B

Patient 002





FIG. 10

C



D




FIG. 10

A. CLASSIFICATION OF SUBJECT MATTER**C07K 16/40(2006.01)i, C07K 16/46(2006.01)i, G01N 33/53(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
C07K 16/40; C07K 16/46; G01N 33/53Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean utility models and applications for utility models
Japanese utility models and applications for utility modelsElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal) & Keywords: myo-inositol oxygenase, antibody, kidney injury, marker**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ARNER et al., 'Molecular cloning, expression, and characterization of myo-inositol oxygenase from mouse, rat, and human kidney' Biochemical and Biophysical Research Communications, Vol.324, No.4, pp.1386-1392 (2004) See abstract; pages 1387, 1391-1392; and figure 2.	1-5, 10, 12-16
A	NCBI, Reference sequence no. NP_060054.4 (05 December 2012) See the whole sequence.	1-5, 10, 12-16
A	ARNER et al., 'Expression of myo-inositol oxygenase in tissues susceptible to diabetic complications' Biochemical and Biophysical Research Communications, Vol.339, No.3, pp.816-820 (2006) See the whole document.	1-5, 10, 12-16
A	XIE et al., 'Pathobiology of renal-specific oxidoreductase/myo-inositol oxygenase in diabetic nephropathy: its implications in tubulointerstitial fibrosis' American Journal of Physiology-Renal Physiology, Vol.298, No.6, pp.F1393-F1404 (2010) See the whole document.	1-5, 10, 12-16

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 2014 (27.10.2014)

Date of mailing of the international search report

28 October 2014 (28.10.2014)

Name and mailing address of the ISA/KR

International Application Division
Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City, 302-701,
Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

LIM, Hea Joon

Telephone No. +82-42-481-8395



Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 17-29
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 17-29 pertain to diagnostic methods practised on the human, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2. Claims Nos.: 6-9
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Since claims 6-9 do not contain the essential feature of the rest of the CDRs forming the antibody, claims 6-9 do not comply with PCT Article 6.
3. Claims Nos.: 11
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US2014/046383

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PRABHU et al., 'Up-regulation of human myo-inositol oxygenase by hyperosmotic stress in renal proximal tubular epithelial cells' The Journal of Biological Chemistry, Vol.280, No.20, pp.19895-19901 (2005) See the whole document.	1-5, 10, 12-16
PX	GAUT et al., 'Development of an immunoassay for the kidney-specific protein myo-inositol oxygenase, a potential biomarker of acute kidney injury' Clinical Chemistry, Vol.60, No.5, pp.747-757 (May 2014) See the whole document.	1-5, 10, 12-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2014/046383

Patent document
cited in search report

Publication
date

Patent family
member(s)

Publication
date

None

专利名称(译)	MIOX抗体和测定		
公开(公告)号	EP3019529A1	公开(公告)日	2016-05-18
申请号	EP2014822351	申请日	2014-07-11
[标]申请(专利权)人(译)	圣路易斯华盛顿大学		
申请(专利权)人(译)	华盛顿大学		
当前申请(专利权)人(译)	华盛顿大学		
[标]发明人	GAUT JOSEPH P LADENSON JACK CRIMMINS DAN MODUR VIJAY		
发明人	GAUT, JOSEPH P. LADENSON, JACK CRIMMINS, DAN MODUR, VIJAY		
IPC分类号	C07K16/40 C07K16/46 G01N33/53 G01N33/573 G01N33/68		
CPC分类号	G01N33/573 C07K16/40 C07K2317/33 C07K2317/34 C07K2317/565 G01N33/6893 G01N2333/90241 G01N2800/347		
优先权	61/845108 2013-07-11 US		
其他公开文献	EP3019529A4		
外部链接	Espacenet		

摘要(译)

本发明涉及用于检测受试者的肾损伤的组合物和方法，例如与急性肾损伤相关的近端肾小管损伤。